Levels of expression of endothelial markers specific to tumour-associated endothelial cells and their correlation with prognosis in patients with breast cancer

被引:91
作者
Davies, G
Cunnick, GH
Mansel, RE
Mason, MD
Jiang, WG
机构
[1] Univ Wales Coll Med, Dept Surg, Metastasis Res Grp, Cardiff CF14 4XN, S Glam, Wales
[2] Velindre Hosp, Dept Med, Sect Clin Oncol, Cardiff, S Glam, Wales
关键词
angiogenesis; breast cancer; Q-RT-PCR; TEMs;
D O I
10.1023/B:CLIN.0000017168.83616.d0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Tumour endothelial markers (TEMs) are a newly discovered family of endothelial markers associated with tumour specific angiogenesis. This study sought to examine the levels of expression for TEMs in human breast cancer. Breast cancer tissues (n=120) together with normal background tissues (n=33) were obtained after surgery. RNA was extracted from frozen sections for gene amplification. The expression of TEMs was assessed using RT-PCR and the quantity of their transcripts was determined using real-time-quantitative PCR (Q-RT-PCR). TEM-7R (P=0.05) and TEM-8 (P<0.01) were significantly raised in breast cancer tissues compared with the levels detected in normal background tissues. After a median follow-up of 72.2 months it was found that patients who had recurrent disease and/or who had died from breast cancer had a significantly (P<0.05) elevated level of TEM-1 compared to those patients who were disease free. In addition, elevated levels of TEM-4, TEM-5, TEM-6, TEM-7 and TEM-7R were also raised in breast cancer tissues. Patients who had developed nodal involvement exhibited significantly (P<0.05) high levels of TEM-1 and TEM-7R compared to patients who were node negative. Furthermore, the levels of TEMs did not correlate with tumour or histological grade. We conclude that elevated levels of TEM-1, TEM-7R and TEM-8 (but not TEM-2, 4, 5, 6 and 7) are associated with either nodal involvement, and/or disease progression, and may therefore, have a prognostic value in breast cancer.
引用
收藏
页码:31 / 37
页数:7
相关论文
共 33 条
  • [1] Carson-Walter EB, 2001, CANCER RES, V61, P6649
  • [2] CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
  • [3] 2-H
  • [4] COLOMBATTI A, 1991, BLOOD, V77, P2305
  • [5] Cunnick GH, 2002, HISTOL HISTOPATHOL, V17, P863, DOI 10.14670/HH-17.863
  • [6] The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo
    Davies, G
    Mason, MD
    Martin, TA
    Parr, C
    Watkins, G
    Lane, J
    Matsumoto, K
    Nakamura, T
    Jiang, WG
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (03) : 348 - 354
  • [7] Ligand recognition by the I domain-containing integrins
    Dickeson, SK
    Santoro, SA
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 1998, 54 (06) : 556 - 566
  • [8] Feldman AL, 2000, CANCER-AM CANCER SOC, V89, P1181
  • [9] PITUITARY FOLLICULAR CELLS SECRETE A NOVEL HEPARIN-BINDING GROWTH-FACTOR SPECIFIC FOR VASCULAR ENDOTHELIAL-CELLS
    FERRARA, N
    HENZEL, WJ
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 161 (02) : 851 - 858
  • [10] FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO